Cargando…
Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”
Targeted immune checkpoint blockade augments anti-tumor immunity and induces durable responses in patients with melanoma and other solid tumors. It also induces specific “immune-related adverse events” (irAEs). IrAEs mainly include gastrointestinal, dermatological, hepatic and endocrinological toxic...
Autores principales: | Gelao, Lucia, Criscitiello, Carmen, Esposito, Angela, Goldhirsch, Aron, Curigliano, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968368/ https://www.ncbi.nlm.nih.gov/pubmed/24594636 http://dx.doi.org/10.3390/toxins6030914 |
Ejemplares similares
-
Best management of locally advanced inoperable breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2013) -
Immune approaches to the treatment of breast cancer, around the corner?
por: Criscitiello, Carmen, et al.
Publicado: (2014) -
Impact of autoimmune diseases on outcome of patients with early breast cancer
por: Criscitiello, Carmen, et al.
Publicado: (2016) -
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018) -
Vaginal Leptothrix: An Innocent Bystander?
por: Vieira-Baptista, Pedro, et al.
Publicado: (2022)